Isaac Gatwood, MD
Family Medicine · Bristow, INNPI 1629330071
Payments from drug & device makers
Across 378 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$886
- Novo Nordisk$698
- Pfizer$409
- Lilly USA, LLC$322
- Takeda Pharmaceuticals U.S.A., Inc.$318
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,660100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,148 |
| AbbVie(2 entities) | 78 | $886 |
| Novo Nordisk | 43 | $698 |
| Pfizer | 29 | $409 |
| Lilly USA, LLC | 24 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $318 |
| Amgen | 20 | $305 |
| Bayer | 15 | $266 |
| GSK | 15 | $239 |
| Boehringer Ingelheim | 9 | $131 |
| Eisai Inc. | 7 | $97 |
| Novartis | 6 | $94 |
| Johnson & Johnson | 5 | $82 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Dexcom, Inc. | 3 | $49 |
| Corium, LLC | 2 | $41 |
| Mylan Specialty L.p. | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Merck | 2 | $31 |
| Ardelyx, Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Abbott | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$5,669 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 172 | $137,431 |
| EliquisApixaban | 87 | $90,541 |
| OzempicSemaglutide | 75 | $74,313 |
| TrulicityDulaglutide | 47 | $67,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $60,038 |
| MounjaroTirzepatide | 39 | $45,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $38,678 |
| JardianceEmpagliflozin | 35 | $31,358 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $27,564 |
| BelsomraSuvorexant | 52 | $26,784 |
| JanuviaSitagliptin Phosphate | 21 | $23,257 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $21,102 |
| VraylarCariprazine Hcl | 12 | $17,525 |
| TrintellixVortioxetine Hydrobromide | 21 | $16,096 |
| XareltoRivaroxaban | 16 | $14,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,148 | $182,824237 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $322 | $113,02286 claims |
| PfizerEliquis | $409 | $90,54187 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $239 | $80,44598 claims |
| Novo NordiskOzempic | $698 | $74,31375 claims |
| MerckBelsomra, Januvia | $31 | $50,04173 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $131 | $45,83665 claims |
| AbbVieVraylar, Linzess | $886 | $24,42424 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $318 | $21,99736 claims |
| Johnson & JohnsonXarelto | $82 | $14,20216 claims |
| Eisai Inc.Dayvigo | $97 | $6,77817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Bristow
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.